<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79027">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02029846</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00052707</org_study_id>
    <nct_id>NCT02029846</nct_id>
  </id_info>
  <brief_title>Glycemia in Diabetic Elders Trial</brief_title>
  <official_title>Glycemia in Diabetic Elders Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pilot randomized controlled trial of 30 elderly type 2 diabetes patients
      conducted at the MODEL Clinical Research (MODEL), Research Division of Bay West
      Endocrinology Associates in Baltimore, Maryland. The investigators hypothesized that
      compared to a regimen base solely on traditional drugs, a regimen including newer drugs will
      achieve glycemic target faster and induce less hypoglycemia, weight gain, and other side
      effects, over the short run.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to achieve glycemic target (HbA1c &lt;7.5%).</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall hypoglycemia measured by glucose meter</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Diabetes Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A regimen with traditional drugs only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Incretin-based Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A regimen including incretin-based drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Treatment (insulin, metformin, sulfonylureas, TZDs)</intervention_name>
    <description>traditional drugs only</description>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>insulin</other_name>
    <other_name>metformin</other_name>
    <other_name>sulfonylureas</other_name>
    <other_name>TZDs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Incretin-Based Treatment (GLP-1, DPP-4, amylin analogues)</intervention_name>
    <description>incretin-based drugs</description>
    <arm_group_label>Incretin-based Treatment</arm_group_label>
    <other_name>GLP-1 analogues and receptor agonists,</other_name>
    <other_name>DPP-4 inhibitors,</other_name>
    <other_name>amylin analogues</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetics diagnosed for at least 6 months

          -  Patients ages â‰¥ 65 years and older

          -  Active patients in the Bay West Endocrinology practice

          -  Inadequately controlled on oral agents and/or basal insulin with HbA1c between 8.0%
             and 12%

          -  Eligible for randomization to either treatment group

          -  Patients willing to follow either treatment arm including regimen using one or more
             injectables

          -  Patients to have an English Reading Level of Grade 6 or above

          -  Patients residing at home

        Exclusion Criteria:

          -  Unwilling to use a regimen that may contain using one or more injections

          -  Using short acting insulin prior to the study

          -  Using GLP-1 in past 10 weeks

          -  History of hypoglycemia unawareness or episodes needing emergency intervention

          -  End-stage renal disease

          -  Dementia

          -  Blindness

          -  Terminal illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsin-Chieh Yeh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bay West Endocrinology Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Hsin-Chieh Yeh</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Incretins</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
